Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfonylureas

B R Zimmerman1

  • 1Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA.

Endocrinology and Metabolism Clinics of North America
|October 6, 1997
PubMed
Summary
This summary is machine-generated.

Sulfonylureas remain a valuable treatment for non-insulin-dependent diabetes mellitus (NIDDM) due to their efficacy, low cost, and safety. Despite potential secondary failure, they are essential for managing hyperglycemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postprandial hyperglycemia: implications for practice.

The American journal of cardiology·2001
Same author

Towards an optimal model for community-based diabetes care: design and baseline data from the Mayo Health System Diabetes Translation Project.

Journal of evaluation in clinical practice·2001
Same author

2000 presidential address: American Diabetes Association.

Diabetes care·2000
Same author

DEMS - a second generation diabetes electronic management system.

Computer methods and programs in biomedicine·2000
Same author

An evaluation of new agents in the treatment of type 2 diabetes.

The Journal of family practice·1998
Same author

Hyperlipidemia and diabetes mellitus.

Mayo Clinic proceedings·1998
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Sulfonylureas have been a cornerstone in managing non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s.
  • The advent of newer oral antidiabetic agents has led some to overlook the continued utility of sulfonylureas.

Purpose of the Study:

  • To re-evaluate the role and benefits of sulfonylurea therapy in the context of modern NIDDM management.
  • To highlight the advantages of sulfonylureas in treating hyperglycemia.

Main Methods:

  • Review of existing literature on sulfonylurea efficacy and safety.
  • Comparative analysis of sulfonylureas against newer oral antidiabetic agents.

Main Results:

  • Sulfonylureas offer advantages including diverse formulations, cost-effectiveness, a favorable side-effect profile, and proven hyperglycemia control.

Related Experiment Videos

  • Secondary failure is a recognized limitation, common to all oral agents as NIDDM progresses.

    • Conclusions:

    • Sulfonylureas continue to be a vital therapeutic option for NIDDM.
    • Their established benefits warrant their inclusion in treatment guidelines for hyperglycemia management.